Abstract:SummaryThe nature of pathogenic mechanisms associated with the development of multiple sclerosis (MS) have long been debated. However, limited research was conducted to define the interplay between infiltrating lymphocytes and resident cells of the central nervous system (CNS). Data presented in this report describe a novel role for astrocyte-mediated alterations to myelin oligodendrocyte glycoprotein (MOG)35–55-specific lymphocyte responses, elicited during the development of experimental autoimmune encephalitomyelitis (EAE). In-vitro studies demonstrated that astrocytes inhibited the proliferation and interferon (IFN)-γ, interleukin (IL)-4, IL-17 and transforming growth factor (TGF)-β secretion levels of MOG35–55-specific lymphocytes, an effect that could be ameliorated by astrocyte IL-27 neutralization. However, when astrocytes were pretreated with IFN-γ, they could promote the proliferation and secretion levels of MOG35–55-specific lymphocytes, coinciding with apparent expression of major histocompatibility complex (MHC)-II on astrocytes themselves. Quantitative polymerase chain reaction (qPCR) demonstrated that production of IL-27 in the spinal cord was at its highest during the initial phases. Conversely, production of IFN-γ in the spinal cord was highest during the peak phase. Quantitative analysis of MHC-II expression in the spinal cord showed that there was a positive correlation between MHC-II expression and IFN-γ production. In addition, astrocyte MHC-II expression levels correlated positively with IFN-γ production in the spinal cord. These findings suggested that astrocytes might function as both inhibitors and promoters of EAE. Astrocytes prevented MOG35–55-specific lymphocyte function by secreting IL-27 during the initial phases of EAE. Then, in the presence of higher IFN-γ levels in the spinal cord, astrocytes were converted into antigen-presenting cells. This conversion might promote the progression of pathological damage and result in a peak of EAE severity.

IL-33 and HMGB1 modulate the progression of EAE via oppositely regulating each other

Interleukin-33 is Released in Spinal Cord and Suppresses Experimental Autoimmune Encephalomyelitis in Mice.

HMGB1 from Astrocytes Promotes EAE by Influencing the Immune Cell Infiltration-Associated Functions of BMECs in Mice

IKKβ-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier

Role of IL-12 Receptor β1 in Regulation of T Cell Response by APC in Experimental Autoimmune Encephalomyelitis

IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice

MiR-409-3p and MiR-1896 Co-Operatively Participate in IL-17-induced Inflammatory Cytokine Production in Astrocytes and Pathogenesis of EAE Mice Via Targeting SOCS3/STAT3 Signaling

Active secretion of IL-33 from astrocytes is dependent on TMED10 and promotes central nervous system homeostasis

Characterization of the Interaction Between Astrocytes and Encephalitogenic Lymphocytes During the Development of Experimental Autoimmune Encephalitomyelitis (EAE) in Mice.

Study on the dynamic expression of IL-17 and RORγt in the experimental autoimmune encephalomyelitis mice

Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood–brain barrier

Act1 Mediates IL-17–induced EAE Pathogenesis Selectively in NG2+ Glial Cells

IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis.

Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood–brain barrier and blood–cerebrospinal fluid barrier

Role of the IL-12/IL-23 System in the Regulation of T-Cell Responses in Central Nervous System Inflammatory Demyelination;

Central Nervous System Expression of Interferon Regulatory Factor 1 Regulates Experimental Autoimmune Encephalomyelitis

[Expression of EBI3 and P28 Mrna in the Brain and Spinal Cord of Chronic Model of Experimental Autoimmune Encephalomyelitis in C57BL/6J Mice].

JAK inhibition ameliorated experimental autoimmune encephalomyelitis by blocking GM-CSF-driven inflammatory signature of monocytes

Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis.

Enhanced T cell proliferation, Th17 differentiation and unaltered IL-10 production lead to marginally enhanced development of experimental autoimmune encephalomyelitis in EBI3-deficient mice (114.12)

The Complexity of Cytokine Treatment in Ongoing EAE Induced with MBP Peptide 68–86 in Lewis Rats